Skip to content

Contouring Conformance comparing Barrigel® with Surgical Clips for Post-Lumpectomy Cavity Delineation in Breast Cancer

Contouring Conformance comparing Barrigel® with Surgical Clips for Post-Lumpectomy Cavity Delineation in Breast Cancer

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12623000470695
Enrollment
35
Registered
2023-05-08
Start date
2021-05-28
Completion date
2022-08-17
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to determine whether Barrigel (hyaluronic acid gel) can delineate the tumour bed after breast cancer surgery Who is it for? You may be eligible to join this study if you have been diagnosed with early breast cancer and planned for wide local excision (WLE) and sentinel lymph node biopsy (SLNB) Study details All participants in this study will have both Barrigel and standard surgical clips applied following wide local incision of the breast cancer. Approximately 4-6 weeks after surgery (or after chemotherapy if needed), participants will undergo computed tomography (CT) scans and magnetic resonance imaging (MRI) scans to visualise the gel and clip placements. A group of doctors will then independently contour out where they think the tumour bed is, and the degree of overlap of each contour will help determine its efficacy. Participants will then be assessed annually for up to 2 years using routine surveillance breast mammography and ultrasound to determine gel presence and characteristics over the long-term. It is hoped that this research project will provide us more information about alternative ways to improve the accuracy of post-operative radiotherapy planning and treatment in early breast cancer, especially as MRI guided planning and treatment becomes more prevalent.

Interventions

Participants with newly diagnosed early breast cancers planned for breast conserving surgery attend the hospital for surgery. In the operating theatre, following wide local excision of the breast cancer, the breast surgeon injects Barrigel (Non-animal stabilised hyaluronic acid gel) in the form of drops, with the goal to mark the deep and radial margins of the excision cavity. This involves drops (approximately 0.3 – 0.5 millilitres) injected using a sterile 21-23 gauge needle, starting at the

Participants with newly diagnosed early breast cancers planned for breast conserving surgery attend the hospital for surgery. In the operating theatre, following wide local excision of the breast cancer, the breast surgeon injects Barrigel (Non-animal stabilised hyaluronic acid gel) in the form of drops, with the goal to mark the deep and radial margins of the excision cavity. This involves drops (approximately 0.3 – 0.5 millilitres) injected using a sterile 21-23 gauge needle, starting at the base, injected just under the pectoral fascia at 4 points of the compass, indicating the deep margin. Further 4 drops are injected approximately 1cm interval above the base plane, also at 4 points of the compass, but at 1cm into the cavity wall, into the adjacent breast tissue. This is repeated at further 1cm intervals above the previous injection plane until the skin was reached. Standard surgical clips are also placed as markers at the same time to indicate the deep, radial and superficial margins of the excision cavity (approximately 4 to 6 clips are used). Following surgery and adequate recovery (approximately 1 to 2 months, or later if the participants undergo adjuvant chemotherapy), participants attend the radiation oncology outpatient department for CT and MRI simulation planning scans, in preparation for their adjuvant radiotherapy treatment. For the study, the scan images are de-identified and provided to radiation oncologists and radiologist to delineate the tumour bed aided by clips on CT, and gel on MRI. These are then further evaluated for consistency and other characteristics. The study participants' future surveillance breast imaging is then monitored for presence of the gel and its characteristics.

Sponsors

Austin Health
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Female patients with clinically node negative, unifocal early breast cancer, measuring a maximum diameter of 3 centimetre (cm), planned for wide local excision (WLE) and sentinel lymph node biopsy (SLNB) were eligible for the study. The breast carcinoma could be of any grade, oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) status.

Exclusion criteria

Patients with allergy to hyaluronic acid, contraindication to magnetic resonance imaging (MRI), or who are unsuitable for RT (eg. active pregnancy, previous ipsilateral breast RT).

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026